Literature DB >> 27091049

Long-Term Outcomes of Biliopancreatic Diversion on Glycemic Control, Insulin Sensitivity and Beta Cell Function.

Ana Carolina Junqueira Vasques1,2, José Carlos Pareja3,4, Maria da Saúde de Oliveira3, Fernanda Satake Novaes3, Marcelo Miranda Oliveira Lima3, Élinton A Chaim4, Francesca Piccinini5, Chiara Dalla Man5, Claudio Cobelli5, Bruno Geloneze3.   

Abstract

BACKGROUND: We aimed to assess the long-term outcomes of biliopancreatic diversion (BPD) surgery on glycemic control, insulin sensitivity (IS), and beta cell function using complementary oral and intravenous dynamic tests.
METHODS: A total of 57 women were divided into three groups: 19 lean, 18 obese (both groups with normal glucose tolerance (NGT)), and 20 obese with type 2 diabetes who underwent BPD and were reassessed 12 months after the procedure. OGTTs and hyperglycemic clamps (HG) were performed. Mathematical modeling was used to analyze IS, beta cell function, and delayed time of beta cell response. The basal, dynamic (first phase/steps of insulin secretion), and static (second phase/steps of insulin secretion) disposition indexes were calculated.
RESULTS: After surgery, the patients exhibited improvements in glycemic control and 15 patients achieved diabetes remission. The surgical patients demonstrated normalized IS in OGGT and HG tests compared to the control groups. The basal beta cell function was improved but remained impaired compared to the Lean NGT group. The stimulated beta cell function parameters showed marked improvements regarding the intravenous stimulus and the second phase/distal steps of insulin secretion. The delay time markedly decreased and became normalized in both dynamic tests.
CONCLUSIONS: The common physiopathology features of type 2 diabetes, i.e., impaired IS and beta cell dysfunction, were demonstrated to be primarily functional and were likely to be reversible to some degree after the BPD. The marked long-term improvement in glycemic control after BPD was closely related to IS improvement and mainly by the recovery of several beta cell physiological features.

Entities:  

Keywords:  Beta cell function; Biliopancreatic diversion; Hyperglycemic clamp; Insulin resistance; Insulin secretion; Obesity; Remission; Type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27091049     DOI: 10.1007/s11695-016-2159-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  31 in total

1.  Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.

Authors:  E Breda; M K Cavaghan; G Toffolo; K S Polonsky; C Cobelli
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

2.  The oral glucose minimal model: estimation of insulin sensitivity from a meal test.

Authors:  Chiara Dalla Man; Andrea Caumo; Claudio Cobelli
Journal:  IEEE Trans Biomed Eng       Date:  2002-05       Impact factor: 4.538

3.  Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery.

Authors:  Stefania Camastra; Melania Manco; Andrea Mari; Aldo V Greco; Silvia Frascerra; Geltrude Mingrone; Ele Ferrannini
Journal:  Diabetes Care       Date:  2007-04       Impact factor: 19.112

4.  Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function.

Authors:  A Mari; M Manco; C Guidone; G Nanni; M Castagneto; G Mingrone; E Ferrannini
Journal:  Diabetologia       Date:  2006-07-04       Impact factor: 10.122

5.  Impact of different criteria on type 2 diabetes remission rate after bariatric surgery.

Authors:  A Mas-Lorenzo; D Benaiges; J A Flores-Le-Roux; J Pedro-Botet; J M Ramon; A Parri; M Villatoro; J Chillarón; M Pera; L Grande; A Goday
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

6.  Beta-cell function improvement after biliopancreatic diversion in subjects with type 2 diabetes and morbid obesity.

Authors:  Lucia Briatore; Barbara Salani; Gabriella Andraghetti; Davide Maggi; Gian Franco Adami; Nicola Scopinaro; Renzo Cordera
Journal:  Obesity (Silver Spring)       Date:  2010-02-25       Impact factor: 5.002

Review 7.  The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence.

Authors:  Jiajie Yu; Xu Zhou; Ling Li; Sheyu Li; Jing Tan; Youping Li; Xin Sun
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

8.  Restoration of acute insulin response in T2DM subjects 1 month after biliopancreatic diversion.

Authors:  Lucia Briatore; Barbara Salani; Gabriella Andraghetti; Cristina Danovaro; Elsa Sferrazzo; Nicola Scopinaro; Gian F Adami; Davide Maggi; Renzo Cordera
Journal:  Obesity (Silver Spring)       Date:  2008-01       Impact factor: 5.002

9.  Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms.

Authors:  Brenno Astiarraga; Amalia Gastaldelli; Elza Muscelli; Simona Baldi; Stefania Camastra; Andrea Mari; Francesco Papadia; Giovanni Camerini; Gianfranco Adami; Nicola Scopinaro; Ele Ferrannini
Journal:  J Clin Endocrinol Metab       Date:  2013-05-10       Impact factor: 5.958

10.  First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery.

Authors:  Serenella Salinari; Alessandro Bertuzzi; Simone Asnaghi; Caterina Guidone; Melania Manco; Geltrude Mingrone
Journal:  Diabetes Care       Date:  2008-11-25       Impact factor: 19.112

View more
  2 in total

1.  Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials.

Authors:  Claudio Cobelli; Chiara Dalla Man
Journal:  J Diabetes Sci Technol       Date:  2021-05-25

Review 2.  The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.

Authors:  Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 25.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.